Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

Rhea-AI Summary

Cognition Therapeutics (NASDAQ: CGTX) will host an investor webcast on July 29, 2024, to discuss results from the Phase 2 SHINE study of CT1812 in mild-to-moderate Alzheimer's disease. The study enrolled 153 adults, randomized to receive 100mg or 300mg of CT1812 or placebo daily for six months. Clinical findings, safety, cognitive and functional endpoints will be presented at the Alzheimer's Association's International Conference in Philadelphia. Additional presentations will cover biomarker and proteomic analyses from CSF samples, and results of a meta-analysis from the SPARC study and SHINE-A participants. The webcast will feature company management, study investigator Dr. Everard Vijverberg, and Alzheimer's expert Dr. Martin J. Sadowski.

Positive

• Phase 2 SHINE study results for CT1812 in Alzheimer's disease to be presented
• Multiple presentations scheduled at the Alzheimer's Association's International Conference
• Study enrolled 153 adults with mild-to-moderate Alzheimer's disease
• Results of proteomic analyses accepted for publication in Alzheimer's & Dementia journal

Negative

• None.

PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer’s disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by clicking here. The event will also be archived on the Investor Relations section of the Cognition website.

Clinical findings from the SHINE study, including safety and cognitive and functional endpoints will be described in a poster presentation on Monday, July 29 in person at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024. Biomarker and proteomic analyses from SHINE participants who provided cerebrospinal fluid (CSF) samples will also be reported on Monday.

In addition, results of a meta-analysis of phosphoproteomics from the 23-patient SPARC study and the first 24 SHINE participants (SHINE-A) will be presented on Sunday, July 28. Results of proteomic analyses from this meta-analysis were recently accepted for publication in Alzheimer's & Dementia, the Journal of the Alzheimer's Association.

AAIC Presentation details

Sunday, July 28, 2024 (8:30a.m. - 4:15p.m. ET)

	1.	Abstract #95147: CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease

Monday, July 29, 2024 (8:30a.m. - 4:15p.m. ET)

	2.	Abstract #89115: Clinical Efficacy Results from COG0201: a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease
	3.	Abstract #95767: Topline CSF Biomarker Outcomes from the Phase 2 Clinical Trial SHINE in Alzheimer's Patients
	4.	Abstract #95770: Exploratory CSF Proteomics Biomarker Outcomes of the Phase 2 Clinical Trial Shine to Assess the Effects of Ct1812 in Alzheimer’s Patients

Date and Time: Monday July 29, 8:30 A.M.

Webcast Details:
Company management will be joined by an investigator in the SHINE study, Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam, who will present an overview of the Phase 2 COG0201 “SHINE” study results. In addition, Martin J. Sadowski, MD, PhD, DSci of New York University School of Medicine will participate as an Alzheimer’s industry expert. A virtual question and answer session will follow formal presentations. Interested parties may register for the event by visiting the Cognition Therapeutics Investor Relations webpage under News & Events or directly by visiting https://lifescievents.com/event/cognitiontherapeutics/.

About the SHINE Study
The SHINE study is a double-blind, placebo-controlled Phase 2 clinical trial which enrolled 153 patients with mild-to-moderate Alzheimer’s disease. Participants were evenly randomized to receive either placebo or one of two doses of CT1812 (100 mg or 300 mg), which was taken orally daily for six months. Endpoints include safety, cognitive function as measured by the ADAS-Cog 11, a globally recognized cognitive scale, and biomarker evidence of disease modification. The SHINE study was supported by two grant awards from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million.

About CT1812
CT1812 is an experimental orally delivered small molecule that penetrates the blood-brain barrier and binds selectively to the sigma-2 (σ-2) receptor complex. Preclinical and clinical data demonstrate that this binding results in the displacement of toxic Aβ oligomers. The σ-2 receptor complex is involved in the regulation of key cellular processes such as membrane trafficking and autophagy that are damaged by toxic interaction with Aβ oligomers, oxidative stress and other stressors. This damage to sensitive synapses can progress to a loss of synaptic function, which manifests as cognitive impairment and Alzheimer’s disease progression.

Participants are currently being recruited in the START study (NCT05531656) of CT1812 in adults with early Alzheimer’s disease; and the MAGNIFY study (NCT05893537) in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration. Enrollment has completed in the SHIMMER study (NCT05225415) of CT1812 in adults with dementia with Lewy bodies and the aforementioned SHINE Study.

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information:   Cognition Therapeutics, Inc.    info@cogrx.com	Casey McDonald (media)  Tiberend Strategic Advisors, Inc.     cmcdonald@tiberend.com	Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com

FAQ

What are the key findings from Cognition Therapeutics' Phase 2 SHINE study for CT1812 (CGTX)?

The key findings from the Phase 2 SHINE study of CT1812 for mild-to-moderate Alzheimer's disease will be presented on July 29, 2024. The study results will include clinical efficacy, safety, cognitive and functional endpoints, as well as biomarker and proteomic analyses from cerebrospinal fluid samples.

When and where will Cognition Therapeutics (CGTX) present the SHINE study results?

Cognition Therapeutics will present the SHINE study results at the Alzheimer's Association's International Conference in Philadelphia, PA, from July 28-August 1, 2024. They will also host an investor webcast on July 29, 2024, at 8:30 a.m. ET to discuss the findings.

How many participants were enrolled in Cognition Therapeutics' SHINE study for CT1812 (CGTX)?

The Phase 2 SHINE study enrolled 153 adults with mild-to-moderate Alzheimer's disease. Participants were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months.

What additional data will be presented alongside the SHINE study results for Cognition Therapeutics (CGTX)?

In addition to the SHINE study results, Cognition Therapeutics will present a meta-analysis of phosphoproteomics from the 23-patient SPARC study and the first 24 SHINE participants (SHINE-A). Results of proteomic analyses from this meta-analysis have been accepted for publication in Alzheimer's & Dementia journal.